FDA
-
-
-
-
-
-
-
VERASTEM doses first patient in Phase 2 pancreatic cancer trial
-
-
-
-
-
-
-
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
-
-
-
-
-
-
-
Verastem Oncology reports $30.9 million in 2025 drug revenue
-
-
-
-
-
-
-
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
-
-
-
-
-
-
-
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
-
-
-
-
-
-
-
Verastem publishes phase 2 trial results in Journal of Clinical Oncology
-
-
-
-
-
-
-
Verastem Oncology (VSTM) announces positive results from phase 1/2 trial on Avutometinib plus Defactinib
-
326,269 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

